Helix Biopharma Corp Stock Performance
| HBP Stock | CAD 2.11 0.01 0.48% |
The company retains a Market Volatility (i.e., Beta) of -1.08, which attests to a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Helix BioPharma are expected to decrease slowly. On the other hand, during market turmoil, Helix BioPharma is expected to outperform it slightly. Helix BioPharma Corp right now retains a risk of 3.99%. Please check out Helix BioPharma accumulation distribution, and the relationship between the value at risk and day typical price , to decide if Helix BioPharma will be following its current trending patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Over the last 90 days Helix BioPharma Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Helix BioPharma is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:5 | Last Split Date 2024-08-16 |
1 | Will Helix BioPharma Corp. stock hit analyst forecasts - CPI Data Low Volatility Stock Recommendations - Newser | 12/04/2025 |
2 | Helix BioPharma Shares Pass Below 50 Day Moving Average - Heres Why - MarketBeat | 12/18/2025 |
3 | Biotech investor Cormorant secures 150M for another SPAC deal - BioPharma Dive | 01/26/2026 |
| Begin Period Cash Flow | 1.1 M | |
| Total Cashflows From Investing Activities | 17 K |
Helix |
Helix BioPharma Relative Risk vs. Return Landscape
If you would invest 217.00 in Helix BioPharma Corp on October 29, 2025 and sell it today you would lose (6.00) from holding Helix BioPharma Corp or give up 2.76% of portfolio value over 90 days. Helix BioPharma Corp is generating 0.0321% of daily returns assuming 3.9891% volatility of returns over the 90 days investment horizon. Simply put, 35% of all stocks have less volatile historical return distribution than Helix BioPharma, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Helix BioPharma Target Price Odds to finish over Current Price
The tendency of Helix Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.11 | 90 days | 2.11 | about 80.43 |
Based on a normal probability distribution, the odds of Helix BioPharma to move above the current price in 90 days from now is about 80.43 (This Helix BioPharma Corp probability density function shows the probability of Helix Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon Helix BioPharma Corp has a beta of -1.08. This usually indicates Additionally Helix BioPharma Corp has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Helix BioPharma Price Density |
| Price |
Predictive Modules for Helix BioPharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Helix BioPharma Corp. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Helix BioPharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Helix BioPharma is not an exception. The market had few large corrections towards the Helix BioPharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Helix BioPharma Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Helix BioPharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.05 | |
β | Beta against Dow Jones | -1.08 | |
σ | Overall volatility | 0.14 | |
Ir | Information ratio | -0.05 |
Helix BioPharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Helix BioPharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Helix BioPharma Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Helix BioPharma Corp had very high historical volatility over the last 90 days | |
| Helix BioPharma Corp has high likelihood to experience some financial distress in the next 2 years | |
| Helix BioPharma Corp has accumulated 335 K in total debt. Helix BioPharma Corp has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Helix BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Helix BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Helix BioPharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Helix to invest in growth at high rates of return. When we think about Helix BioPharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.21 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Helix BioPharma Corp has accumulated about 938 K in cash with (3.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 29.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Biotech investor Cormorant secures 150M for another SPAC deal - BioPharma Dive |
Helix BioPharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Helix Stock often depends not only on the future outlook of the current and potential Helix BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Helix BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 55.7 M | |
| Cash And Short Term Investments | 65 K |
Helix BioPharma Fundamentals Growth
Helix Stock prices reflect investors' perceptions of the future prospects and financial health of Helix BioPharma, and Helix BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Helix Stock performance.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 160.25 M | ||||
| Shares Outstanding | 76.38 M | ||||
| Price To Earning | (7.09) X | ||||
| Price To Book | 9.98 X | ||||
| EBITDA | (5.21 M) | ||||
| Net Income | (5.21 M) | ||||
| Cash And Equivalents | 938 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 335 K | ||||
| Current Ratio | 0.37 X | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (3.83 M) | ||||
| Earnings Per Share | (0.07) X | ||||
| Market Capitalization | 161.16 M | ||||
| Total Asset | 18.8 M | ||||
| Retained Earnings | (215.88 M) | ||||
| Working Capital | (123 K) | ||||
About Helix BioPharma Performance
By examining Helix BioPharma's fundamental ratios, stakeholders can obtain critical insights into Helix BioPharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Helix BioPharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 4.5 K | 4.7 K | |
| Return On Tangible Assets | (14.49) | (13.77) | |
| Return On Capital Employed | (0.31) | (0.30) | |
| Return On Assets | (0.32) | (0.33) | |
| Return On Equity | (0.30) | (0.29) |
Things to note about Helix BioPharma Corp performance evaluation
Checking the ongoing alerts about Helix BioPharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Helix BioPharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Helix BioPharma Corp had very high historical volatility over the last 90 days | |
| Helix BioPharma Corp has high likelihood to experience some financial distress in the next 2 years | |
| Helix BioPharma Corp has accumulated 335 K in total debt. Helix BioPharma Corp has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Helix BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Helix BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Helix BioPharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Helix to invest in growth at high rates of return. When we think about Helix BioPharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.21 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Helix BioPharma Corp has accumulated about 938 K in cash with (3.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 29.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Biotech investor Cormorant secures 150M for another SPAC deal - BioPharma Dive |
- Analyzing Helix BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Helix BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining Helix BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Helix BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Helix BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Helix BioPharma's stock. These opinions can provide insight into Helix BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.